{"id":3837,"date":"2025-03-31T18:11:50","date_gmt":"2025-03-31T18:11:50","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/cilazapril-txt\/"},"modified":"2025-03-31T18:11:50","modified_gmt":"2025-03-31T18:11:50","slug":"cilazapril-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/cilazapril-txt\/","title":{"rendered":"Cilazapril.txt"},"content":{"rendered":"

Cilazapril<\/h1>\n

CLINICAL USE <\/H3>
\nAngiotensin-converting enzyme inhibitor: Hypertension, heart failure

DOSE IN NORMAL RENAL FUNCTION <\/H3>0.5\u20135 mg daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :435.5<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 80\u201390<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.5\u20130.8<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :9\/Increased

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>40\u201350 Start at low dose and adjust according to response10\u201340 Start at low dose and adjust according to response
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Start at low dose and adjust according to response

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • HDF\/high flux &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR=10\u201340 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsAnaesthetics: enhanced hypotensive effect Ciclosporin: decreased renal function and increased risk of hyperkalaemiaNSAIDs: antagonism of hypotensive effect and increased risk of renal failure; hyperkalaemiaDiuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diureticsEpoetin: increased risk of hyperkalaemia Lithium: ACE inhibitors reduce excretion of lithium (increased plasma lithium concentration)Potassium salts: hyperkalaemia Tacrolimus: decreased renal function and increased risk of hyperkalaemia

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>Take dose about the same time each day

    OTHER INFORMATION <\/H4>Data refer to active drug \u2013 cilazaprilat Symptomatic hypotension reported in patients with sodium or volume depletion, i.e. sickness, diarrhoea, on diuretics, low sodium diet or post dialysisRenal failure has been associated with ACE inhibitors in patients with renal artery stenosis, post renal transplant, and congestive heart failure. A high incidence of anaphylactoid reactions has been reported in patients dialysed with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor \u2013 this combination should therefore be avoidedHyperkalaemia and other side effects are more common in patients with impaired renal functionClose monitoring of renal function during therapy is necessary in those with renal insufficiency
    \n","protected":false},"excerpt":{"rendered":"

    Cilazapril CLINICAL USE Angiotensin-converting enzyme inhibitor: Hypertension, heart failure DOSE<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3837","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3837"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3837\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}